A Phase II trial of MN-166 (ibudilast) in combination with temozolomide (TMZ) for the treatment of Grade IV Glioblastoma.
Phase of Trial: Phase II
Latest Information Update: 09 May 2018
At a glance
- Drugs Ibudilast (Primary) ; Temozolomide (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- 09 May 2018 According to a MediciNova media release, the U.S. Food and Drug Administration (FDA) has accepted the IND for MN-166 in combination with temozolomide for treatment of GBM.
- 08 Mar 2017 New trial record